VIVO 16.91 Meridian Bioscience Inc $VIVO Hit a 52 week low of 16.53 Closing the day 10:45 at 16.91 +0.03 +0.18% With a day low of 16.53 and a total volume of 119,862.
VIVO Recent Posts: http://investorshangout.com/Meridian-Bioscien...IVO-55809/
VIVO Meridian Bioscience Inc Recent Headline News
Healthcare's Top Dividend Paying Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 13, 6:43AM CST
Source: Flickr user TaxRebate.org.uk. Dividends are the foundation to which all great long-term portfolio are built. Receiving a payment equal to 2% or 3% per year might not seem like much, but reinvested into that same growing company over the...
VIVO: 16.78 (-0.10), PETS: 13.60 (-0.08), GSK: 45.83 (+0.21), SNY: 46.66 (+0.10), PDLI: 7.93 (-0.09)
Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.36 (-0.05), VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91), OSUR: 9.18 (unch)
Meridian Bioscience Down 13.7% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Mon Nov 10, 9:45AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 13.75% as of today's recent price of $16.91.
VIVO: 16.78 (-0.10)
Meridian Bioscience (VIVO) Falls: Stock Goes Down 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:55AM CST
Meridian Bioscience saw a big move last session, as the company’s shares fell by nearly 6% which continued the recent downtrend
VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91), GWPH: 75.29 (-0.03), OSUR: 9.18 (unch)
Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Fri Nov 07, 6:59AM CST
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Outperform to Neutral at RW Baird today. The stock closed yesterday at $17.91 on volume of 374,000 shares, above average daily volume of 203,000. Over the past year, Meridian Bioscience has traded in a range of $17.12 to $27.72 and closed yesterday at $17.91, 5% above that low. The 200-day and 50-day moving averages have moved 0.73% lower and 0.51% lower over the past week, respectively.
VIVO: 16.78 (-0.10)
Meridian Bioscience misses Street 4Q forecasts
Automated Insights - Thu Nov 06, 10:18AM CST
CINCINNATI (AP) _ Meridian Bioscience Inc. (VIVO) on Thursday reported fiscal fourth-quarter net income of $8.2 million.
VIVO: 16.78 (-0.10)
Meridian Bioscience declares $0.20 dividend
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VIVO: 16.78 (-0.10)
Meridian Bioscience misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:02AM CST
VIVO: 16.78 (-0.10)
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
Business Wire - Thu Nov 06, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO):
VIVO: 16.78 (-0.10)
7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST
KND: 20.42 (-0.36), VIVO: 16.78 (-0.10), PETS: 13.60 (-0.08), PFE: 30.52 (+0.10), GSK: 45.84 (+0.22), MR: 31.46 (-0.03), SEM: 13.63 (-0.01), PDLI: 7.93 (-0.09), SNN: 33.58 (+0.05), AZN: 74.57 (+0.31), MRK: 59.67 (+0.36), STJ: 65.86 (+0.18), TRIB: 17.81 (-0.40), ABBV: 64.00 (+0.24), THRX: 13.36 (+0.04), SNY: 46.66 (+0.10)
Meridian Bioscience Down 9.6% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Thu Oct 23, 9:58AM CDT
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 2 months, Meridian Bioscience has returned 9.61% as of today's recent price of $17.72.
VIVO: 16.78 (-0.10)
Meridian Bioscience Offers Testing Solutions to Premier - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 12:50PM CDT
The illumigene molecular system uses loop-mediated isothermal DNA amplification technology, which is an efficient system to allow Meridian Bioscience (VIVO) to provide customers the illumipro 10 instrument without a capital investment or costly annual service contract.
ICUI: 84.30 (-0.43), SMA: 9.45 (-0.03), VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91)
Meridian Bioscience's Earnings Outlook Show Flat Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:40PM CDT
Meridian Bioscience (VIVO) also expects net revenues to grow in the range of 2 to 5% to approximately between $193 and $200 million for fiscal 2015.
ICUI: 84.30 (-0.43), SMA: 9.45 (-0.03), VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91)
Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae
Business Wire - Wed Sep 03, 6:30AM CDT
Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene(R) molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene molecular platform without individual negotiations.
VIVO: 16.78 (-0.10), PINC: 31.44 (-0.08)
Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2015 and Reaffirms Fiscal 2014 Guidance
Business Wire - Tue Sep 02, 6:30AM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2015 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2015, management expects net revenues to be in the range of $193 to $200 million, or 2% to 5% growth, and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.2 million at fiscal 2014 year end to 42.4 million at fiscal 2015 year end. The revenues and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2015.
VIVO: 16.78 (-0.10)
3 Value Stocks to Consider for Your Portfolio
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 12:32PM CDT
Just as we often examine companies that may be rising past their fair values, we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think it...
VIVO: 16.78 (-0.10), RIG: 26.26 (-0.82), BAGL: 20.23 (-0.01)
Meridian Bioscience partners with University of Tennessee Research Foundation to develop electrokinetic sensor technology
M2 - Thu Aug 07, 6:58AM CDT
Life science company Meridian Bioscience (NasdaqGS:VIVO) announced on Wednesday that it executed a technology and commercial license agreement for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.78 (-0.10)
Meridian Bioscience and the University of Tennessee Research Foundation Enter into a License Agreement for Electrokinetic Sensor Technology
Business Wire - Wed Aug 06, 8:00AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO), today announced that it has entered into a technology and commercial license agreement with the University of Tennessee Research Foundation (UTRF) for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.78 (-0.10)
Meridian Bioscience Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 12:58PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) expects earnings per share between 85 and 90 cents while revenues are expected in the range of $190 to $195 million.
BSX: 13.36 (-0.05), VIVO: 16.78 (-0.10), ALR: 39.91 (-0.19), OSUR: 9.18 (unch)
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
Business Wire - Thu Jul 24, 7:15AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
VIVO: 16.78 (-0.10)
VIVO Recent Posts: http://investorshangout.com/Meridian-Bioscien...IVO-55809/
VIVO Meridian Bioscience Inc Recent Headline News
Healthcare's Top Dividend Paying Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 13, 6:43AM CST
Source: Flickr user TaxRebate.org.uk. Dividends are the foundation to which all great long-term portfolio are built. Receiving a payment equal to 2% or 3% per year might not seem like much, but reinvested into that same growing company over the...
VIVO: 16.78 (-0.10), PETS: 13.60 (-0.08), GSK: 45.83 (+0.21), SNY: 46.66 (+0.10), PDLI: 7.93 (-0.09)
Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.36 (-0.05), VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91), OSUR: 9.18 (unch)
Meridian Bioscience Down 13.7% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Mon Nov 10, 9:45AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 13.75% as of today's recent price of $16.91.
VIVO: 16.78 (-0.10)
Meridian Bioscience (VIVO) Falls: Stock Goes Down 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:55AM CST
Meridian Bioscience saw a big move last session, as the company’s shares fell by nearly 6% which continued the recent downtrend
VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91), GWPH: 75.29 (-0.03), OSUR: 9.18 (unch)
Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Fri Nov 07, 6:59AM CST
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Outperform to Neutral at RW Baird today. The stock closed yesterday at $17.91 on volume of 374,000 shares, above average daily volume of 203,000. Over the past year, Meridian Bioscience has traded in a range of $17.12 to $27.72 and closed yesterday at $17.91, 5% above that low. The 200-day and 50-day moving averages have moved 0.73% lower and 0.51% lower over the past week, respectively.
VIVO: 16.78 (-0.10)
Meridian Bioscience misses Street 4Q forecasts
Automated Insights - Thu Nov 06, 10:18AM CST
CINCINNATI (AP) _ Meridian Bioscience Inc. (VIVO) on Thursday reported fiscal fourth-quarter net income of $8.2 million.
VIVO: 16.78 (-0.10)
Meridian Bioscience declares $0.20 dividend
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VIVO: 16.78 (-0.10)
Meridian Bioscience misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:02AM CST
VIVO: 16.78 (-0.10)
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
Business Wire - Thu Nov 06, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO):
VIVO: 16.78 (-0.10)
7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST
KND: 20.42 (-0.36), VIVO: 16.78 (-0.10), PETS: 13.60 (-0.08), PFE: 30.52 (+0.10), GSK: 45.84 (+0.22), MR: 31.46 (-0.03), SEM: 13.63 (-0.01), PDLI: 7.93 (-0.09), SNN: 33.58 (+0.05), AZN: 74.57 (+0.31), MRK: 59.67 (+0.36), STJ: 65.86 (+0.18), TRIB: 17.81 (-0.40), ABBV: 64.00 (+0.24), THRX: 13.36 (+0.04), SNY: 46.66 (+0.10)
Meridian Bioscience Down 9.6% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Thu Oct 23, 9:58AM CDT
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 2 months, Meridian Bioscience has returned 9.61% as of today's recent price of $17.72.
VIVO: 16.78 (-0.10)
Meridian Bioscience Offers Testing Solutions to Premier - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 12:50PM CDT
The illumigene molecular system uses loop-mediated isothermal DNA amplification technology, which is an efficient system to allow Meridian Bioscience (VIVO) to provide customers the illumipro 10 instrument without a capital investment or costly annual service contract.
ICUI: 84.30 (-0.43), SMA: 9.45 (-0.03), VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91)
Meridian Bioscience's Earnings Outlook Show Flat Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:40PM CDT
Meridian Bioscience (VIVO) also expects net revenues to grow in the range of 2 to 5% to approximately between $193 and $200 million for fiscal 2015.
ICUI: 84.30 (-0.43), SMA: 9.45 (-0.03), VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91)
Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae
Business Wire - Wed Sep 03, 6:30AM CDT
Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene(R) molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene molecular platform without individual negotiations.
VIVO: 16.78 (-0.10), PINC: 31.44 (-0.08)
Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2015 and Reaffirms Fiscal 2014 Guidance
Business Wire - Tue Sep 02, 6:30AM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2015 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2015, management expects net revenues to be in the range of $193 to $200 million, or 2% to 5% growth, and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.2 million at fiscal 2014 year end to 42.4 million at fiscal 2015 year end. The revenues and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2015.
VIVO: 16.78 (-0.10)
3 Value Stocks to Consider for Your Portfolio
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 12:32PM CDT
Just as we often examine companies that may be rising past their fair values, we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think it...
VIVO: 16.78 (-0.10), RIG: 26.26 (-0.82), BAGL: 20.23 (-0.01)
Meridian Bioscience partners with University of Tennessee Research Foundation to develop electrokinetic sensor technology
M2 - Thu Aug 07, 6:58AM CDT
Life science company Meridian Bioscience (NasdaqGS:VIVO) announced on Wednesday that it executed a technology and commercial license agreement for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.78 (-0.10)
Meridian Bioscience and the University of Tennessee Research Foundation Enter into a License Agreement for Electrokinetic Sensor Technology
Business Wire - Wed Aug 06, 8:00AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO), today announced that it has entered into a technology and commercial license agreement with the University of Tennessee Research Foundation (UTRF) for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.78 (-0.10)
Meridian Bioscience Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 12:58PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) expects earnings per share between 85 and 90 cents while revenues are expected in the range of $190 to $195 million.
BSX: 13.36 (-0.05), VIVO: 16.78 (-0.10), ALR: 39.91 (-0.19), OSUR: 9.18 (unch)
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
Business Wire - Thu Jul 24, 7:15AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
VIVO: 16.78 (-0.10)
